Intracellular redox induced drug release in cancerous and mesenchymal stem cells

Alexander S. Timin, Kirill V. Lepik, Albert M. Muslimov, Dmitry A. Gorin, Boris V. Afanasyev, Gleb B. Sukhorukov

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


In this report, we investigated intracellular redox induced drug release in cancerous cells and human mesenchymal stem cells (MSCs) as an example of healthy cells using redox-responsive microcapsules with covalently bonded anti-cancer drug (doxorubicin) via the amine-reactive cross-linker, 3,3′-dithiobis(sulfosuccinimidyl propionate) containing disulfide bond. Such rationally designed capsules with incorporated redox-sensitive cross-linker are capable of controllable Dox release in the presence of glutathione (GSH) due to a thiol-cleavable disulfide bonds. The treatment of human MSCs and human cervical cancer cell line (HeLa) with Dox-conjugated capsules showed that the Dox release was observed only when capsules incubated with HeLa cells which can be induced by high GSH level in cancerous (HeLa) cells. Moreover, the results of cell viability indicated that Dox-conjugated capsules are more effective when inducing cell death of HeLa than free Dox improving the anti-tumor efficacy of chemotherapeutic drug and simultaneously they possess lower cytotoxicity against MSCs compared to cancerous cells. Such properties are important in design of smart drug carriers for efficient cancer therapy.

Original languageEnglish
Pages (from-to)450-458
Number of pages9
JournalColloids and Surfaces B: Biointerfaces
Publication statusPublished - 1 Nov 2016
Externally publishedYes


  • Biodegradation
  • Cancer therapy
  • Glutathione
  • Mesenchymal stem cells
  • Polyelectrolyte capsules


Dive into the research topics of 'Intracellular redox induced drug release in cancerous and mesenchymal stem cells'. Together they form a unique fingerprint.

Cite this